BI Asset Management Fondsmaeglerselskab A S Cuts Stock Position in Stryker Corporation $SYK

BI Asset Management Fondsmaeglerselskab A S lessened its position in Stryker Corporation (NYSE:SYK) by 42.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 19,788 shares of the medical technology company’s stock after selling 14,709 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Stryker were worth $6,955,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker in the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the third quarter valued at approximately $27,000. CGC Financial Services LLC purchased a new position in shares of Stryker in the fourth quarter valued at approximately $29,000. Strive Asset Management LLC purchased a new position in shares of Stryker in the third quarter valued at approximately $30,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in shares of Stryker in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 1.5%

Shares of NYSE:SYK opened at $305.71 on Friday. The firm’s 50 day moving average price is $318.43 and its 200 day moving average price is $345.86. The stock has a market cap of $117.20 billion, a price-to-earnings ratio of 35.38, a price-to-earnings-growth ratio of 1.93 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

SYK has been the subject of several recent research reports. Jefferies Financial Group reissued a “buy” rating and issued a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Needham & Company LLC lowered their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research note on Friday, May 1st. Finally, Citigroup lowered their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and an average target price of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.